Expertise in
4
conditions

Florence Lerebours

Paris, FR 
Expertise in
4
conditions
Paris, FR 

Overview

Florence Lerebours practices practicing medicine in Paris, France.

Ms. Lerebours is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, and Mastectomy.

She is actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

Paris, France
Other Locations
Saint Cloud, France
St Cloud, Sete, France
Rene, France
Toulouse, France
35 Rue Dailly, Rouez, 92210, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
Enrollment Status: Active_not_recruiting
Publish Date: March 18, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Enrollment Status: Completed
Publish Date: November 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab Injection, Neoadjuvant EC-Paclitaxel Chemotherapy
Study Phase: Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

110 Total Publications

Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer.
Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026

Frequently Asked Questions about Florence Lerebours

Is Florence Lerebours a top-rated expert for Inflammatory Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Florence Lerebours is classified as an Elite expert for Inflammatory Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Florence Lerebours participate in research or clinical trials?

Yes. Florence Lerebours has published 110 articles and abstracts on conditions like Inflammatory Breast Cancer. You can view a list of Florence Lerebours's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lerebours's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile